ESSA PHARMA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.69 USD | -0.45% |
|
-13.79% | +1.36% |
| Mar. 06 | Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call | |
| Mar. 06 | Norway's wealth fund pushes for more women on emerging market company boards | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Calendar
2024-05-06
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
9.239
CAD
Average target price
27.08
CAD
Spread / Average Target
+193.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.36% | 297M | |
| -1.68% | 41.35B | |
| +42.15% | 40.38B | |
| +3.17% | 39.05B | |
| -12.11% | 26.67B | |
| +1.87% | 24.07B | |
| -23.68% | 18.36B | |
| -3.67% | 11.68B | |
| +21.18% | 11.6B | |
| +7.59% | 11.15B |
- Stock Market
- Equities
- EPIX Stock
- News ESSA Pharma Inc.
- Earnings Flash (EPIX) ESSA PHARMA Reports Q3 Loss $-0.20
